CYC
CYCLOPHARM LIMITED
$0.4600
▲ +2.22%
Market cap
$58M
Turnover
$304
Last price
$0.4600
Day change
+2.22%
Announcements
5
Range, past year
Open 0.835 · Low 0.450 · Now 0.460 · High 1.475
Open CYC in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
CYC momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-09-28.
Momentum quality
21/100
Wyckoff phase
Downtrend9d
Trend stage
Breakdown
1 Day
+2.2%
1 Week
-4.2%
1 Month
-10.7%
1 Year
-45.2%
RSI
42
Avg daily range
4.7%
CYCLOPHARM LIMITED scores 21 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Breakdown.
On the Wyckoff cycle it sits in Downtrend, where it has been for 9 trading days. The weekly timeframe reads Downtrend, which agrees with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
Points to watch
- 60d drawdown -26.2%
- Thin liquidity
- Risk rating: Very High
- Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highsCYC announcements
Recent price-sensitive releases.
- 2026-08-24 Half Yearly Report and Accounts Half Yearly Report | Half Year Audit Review | Half Year Directors' Statement | Half Year Accounts | Half Year Directors' Report
- 2026-08-24 CYC 1H2026 Results Summary Company Presentation | Half Yearly Report
- 2026-07-29 New US Lung Imaging Guidelines Name Technegas as Preferred A Progress Report
- 2026-07-15 Immediate 11-Site Technegas Rollout at University Hospitals
- 2026-07-02 CYC First-Half 2026 Update
More Health Care stocks
Most traded in the same sector.